Feedback / Questions
cebranopadol (TRN-228) - Tris Pharma
https://www.businesswire.com/news/home/20250306271136/en/Tris-Pharma-Announces-Positive-Results-from-ALLEVIATE-2-Phase-3-Pivotal-Trial-for-Cebranopadol-an-Investigational-First-in-Class-Oral-Dual-NMR-Agonist-for-the-Treatment-of-Moderate-to-Severe-Acute-Pain
Mar 6, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next